AG08C5
PGNMi001-A
General
Donor Information
General Donor Information |
|
Sex | male |
Age of donor (at collection) | 1-4 |
Ethnicity | Asian |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Family history | hiPSC derived from healthy male donor AG08498 fibroblast cells (https://catalog.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=AG08498&Product=CC) |
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
46, XY
|
External Databases (Donor) |
|
BioSamples | SAMN03120540 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Please provide contact information of the holder of the original Donor Information Sheet. | Coriell |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | Yes |
Please provide the contact information | Coriell: https://www.coriell.org/0/Sections/Support/NIA/Model.aspx?PgId=351 |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | No information |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | No |
Is there an MTA available for the cell line? | Yes |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell line name | AG08498 |
Source cell type |
Synonyms
|
Source cell origin | |
Age of donor (at collection) | 1-4 |
Collected in | 1985 |
Reprogramming method |
|
Vector type | Integrating |
Vector | Virus (Lentivirus) |
Genes | |
Is the used vector excisable? |
Unknown |
Absence of reprogramming vector(s)? |
Unknown |
Reprogramming vectors silenced? | |
Vector free reprogramming |
|
Other |
|
Selection criteria for clones | HiPS colonies were picked about 4 to 6 weeks after infection based on ES cell-like morphology. |
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzymatically
TrypLE
|
O2 Concentration | 20 % |
CO2 Concentration | 5 % |
Medium |
Other medium:
Base medium: StemMACS iPS-Brew XF (Miltenyi)
Main protein source: Serum concentration: % |
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
TRA 1-60 |
Yes |
|
||||
TRA 1-81 |
Yes |
|
||||
SSEA-4 |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|||||
NANOG |
Yes |
|
||||
SOX2 |
Yes |
|
Score:
Marker | Present | Absent |
mCpG | ||
OCT4 |
Differentiation Potency
In vitro directed differentiation
Marker | Expressed |
FOXA2 |
Yes |
SOX17 |
Yes |
In vitro directed differentiation
Marker | Expressed |
TBXT |
Yes |
HAND1 |
Yes |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.